Lonza
Lonza is a healthcare manufacturing organization helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. They help their customers to deliver new and innovative medicines that treat a wide range of diseases, allowing their patients to benefit from life-saving and life-enhancing treatments.
Latest Content
Webinar
Manipulating Human Cell Genetics for Cellular Therapies
In this webinar, Dr. Theo Roth will discuss how CRISPR-All can be used to push human genetics beyond their evolved functionality, enabling researchers to engineer synthetic cell states with therapeutic potential.
Webinar
Engineering Cell Models for Therapeutic Development and Screening
On-Demand
In this webinar, our expert speakers will explore how targeted integration techniques can significantly enhance the efficiency and reliability of engineering CHO cell models for drug discovery.
eBook
Drug Discovery: Innovations, Challenges and the Future of Medicine
This eBook explores the latest advancements in drug discovery, from AI-driven precision medicine to the promise and risks of new weight loss drugs.
Online Event
Advances in Drug Discovery & Development 2025
The drug discovery landscape is rapidly evolving with the integration of new technologies and methodologies. Returning for 2025, this event will focus on small molecule and biologic drug development, high-throughput screening and novel drug targets.
Online Event
The Landscape of Cancer Research: Advances in Immuno-oncology 2025
On-Demand
This event will feature discussions on novel immune checkpoint inhibitors, personalized cancer vaccines and CAR T-Cell therapies. We will also address the challenges of translating basic research into clinical practice and future directions.
Product
Advertisement
XS Technologies® - The Microbial Expression Systems for Today’s Therapeutics
Lonza’s XS Technologies® platform, with Pichia and E. coli, enables scalable protein production for 130+ projects, including enzymes and biologics. Flexible tools optimize yield and quality, accelerating therapy development. License XS® for your lab!
App Note / Case Study
Discover a High-Throughput, Real-Time Angiogenic Tube Formation Assay
This application note highlights a high-throughput angiogenic tube formation assay using a co-culture of HUVECs and fibroblasts, enabling efficient and accurate drug discovery screening.
Product News
Lonza Extends Collaboration With Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Lonza, announced a long-term extension of its collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs.
Product
Advertisement
bYlok® Bispecific Pairing Technology: A Close to Nature Solution to Overcome Chain Mispairing
Lonza’s bYlok® technology addresses the challenge of heavy chain-light chain (HC-LC) mispairing in bispecific antibody production.
Product News
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) From Roche
Lonza, announced it has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion.
Advertisement
